Paving the way for optimal disease control in moderate-to-severe type 2 asthma

touchPANEL DISCUSSION for touchIMMUNOLOGY Listen to a panel of experts discuss using biologics to optimize outcomes for patients with type 2 asthma and how biomarkers can inform treatment decisions. The experts Dr Michael Wechsler - National Jewish Health and University of Colorado, Denver, USA Dr Roland Buhl - Mainz University Hospital, Mainz, Germany Dr Flavia Hoyte - National Jewish Health and University of Colorado, Denver, USA This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is provided by touchIME. For further information visit our website: https://touchimmunologyime.org/pd-in-disease-control-in-moderate-to-severe-type-2-asthma/